CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test
At DNA Labs UAE, we offer the CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test. This test analyzes the CD59 gene using Next-Generation Sequencing (NGS) technology to identify any mutations or variations that may be causing the condition.
Test Components and Price
The CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test is priced at 4400.0 AED. The test requires a blood sample, extracted DNA, or one drop of blood on an FTA card.
Report Delivery
After the sample is collected, the report will be delivered within 3 to 4 weeks.
Test Method and Type
The CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test uses NGS technology. It falls under the category of hematology tests and is performed by hematologists in our Genetics department.
Pre Test Information
Before undergoing the CD59 Gene Hemolytic Anemia CD59-Mediated with or without Immune-Mediated Polyneuropathy Genetic Test, it is important to provide the clinical history of the patient. Additionally, a genetic counseling session will be conducted to draw a pedigree chart of family members affected by the condition.
Test Details
The CD59 gene is associated with a condition called hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy. This genetic test uses NGS technology to analyze the DNA sequence of the CD59 gene and identify any mutations or variations that may be causing the condition.
Hemolytic anemia is a disorder characterized by the premature destruction of red blood cells, leading to a decrease in their lifespan. The CD59 protein plays a crucial role in protecting red blood cells from destruction by the immune system. Mutations in the CD59 gene can result in a deficiency or dysfunction of the CD59 protein, leading to the destruction of red blood cells and the development of anemia.
In some cases, individuals with CD59 gene mutations may also develop immune-mediated polyneuropathy, which is a condition characterized by damage to the peripheral nerves. This can result in symptoms such as weakness, numbness, and pain in the limbs.
The NGS genetic test involves sequencing the entire CD59 gene to identify any mutations or variations in the DNA sequence. This can help confirm a diagnosis of hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy and provide information about the specific genetic variant causing the condition.
Genetic testing can be useful in determining the cause of a person’s symptoms, predicting the course of the disease, and guiding treatment decisions. It can also be beneficial for family members who may be at risk of inheriting the condition. However, it is important to note that genetic testing is not always necessary or appropriate for every individual, and the decision to undergo testing should be made in consultation with a healthcare professional or genetic counselor.
| Test Name | CD59 Gene Hemolytic anemia CD59-mediated with or without immune-mediated polyneuropathy Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Hematology |
| Doctor | Hematologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for CD59 Gene Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CD59 Gene Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy NGS Genetic DNA Test gene CD59 |
| Test Details | The CD59 gene is associated with a condition called hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy. This genetic test, known as Next-Generation Sequencing (NGS), is used to analyze the DNA sequence of the CD59 gene to identify any mutations or variations that may be causing the condition. Hemolytic anemia is a disorder characterized by the premature destruction of red blood cells, leading to a decrease in their lifespan. CD59 is a protein that plays a crucial role in protecting red blood cells from destruction by the immune system. Mutations in the CD59 gene can result in a deficiency or dysfunction of the CD59 protein, leading to the destruction of red blood cells and the development of anemia. In some cases, individuals with CD59 gene mutations may also develop immune-mediated polyneuropathy, which is a condition characterized by damage to the peripheral nerves. This can result in symptoms such as weakness, numbness, and pain in the limbs. The NGS genetic test involves sequencing the entire CD59 gene to identify any mutations or variations in the DNA sequence. This can help in confirming a diagnosis of hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy and can also provide information about the specific genetic variant causing the condition. Genetic testing can be useful in determining the cause of a person’s symptoms, predicting the course of the disease, and guiding treatment decisions. It can also be beneficial for family members who may be at risk of inheriting the condition. However, it is important to note that genetic testing is not always necessary or appropriate for every individual, and the decision to undergo testing should be made in consultation with a healthcare professional or genetic counselor. |
